Cutaneous Recall Phenomenon at the Site of Previous Doxorubicin Extravasation After Second-Line Chemotherapy
Open Access
- 17 January 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 99 (2), 177-178
- https://doi.org/10.1093/jnci/djk027
Abstract
Recall inflammatory reactions of the skin have been described in the literature in connection with either prior radiation treatment or following extravasation of cytotoxic agents of the anthracycline family ( 1 – 3 ). Prolonged recall reactions may occur in skin at sites of irradiation, whereas inflammatory recall phenomena at sites of previous drug extravasation are rare and often occur as single events following administration of the same cytotoxic drug ( 1 , 2 ). Here we describe a case of inflammatory recall phenomenon at the site of previous drug extravasation.Keywords
This publication has 7 references indexed in Scilit:
- Recall inflammatory skin reaction after use of pegylated liposomal doxorubicin in site of previous drug extravasationThe Lancet Oncology, 2006
- From Conventional to Stealth Liposomes: a New Frontier in Cancer ChemotherapyJournal of Chemotherapy, 2004
- Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburnGynecologic Oncology, 2004
- Gemcitabine‐related radiation recall preferentially involves internal tissue and organsCancer, 2004
- Extravasation: a dreaded complication of chemotherapyAnnals Of Oncology, 2003
- Recall Phenomenon Following EpirubicinClinical Oncology, 1999
- A prospective study of topical dimethyl sulfoxide for treating anthracycline extravasation.Journal of Clinical Oncology, 1988